Kathryn V. Blake

Kathryn V. Blake

Auto-generated profile, based on publicly available information

Kathryn V. Blake

Center for Pharmacogenomics and Translational Research, Nemours Children's Health, Jacksonville, FL, United States

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
HAHolly Antal
Holly Antal
HBH. Timothy Bunnell
H. Timothy Bunnell
SMSuzanne M. McCahan
Suzanne M. McCahan
CPChris Pennington
Chris Pennington
TWTim Wysocki
Tim Wysocki
KBKathryn V. Blake
Kathryn V. Blake

1 October 2020 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
HSHyun Jin Song
Hyun Jin Song
KBKathryn V Blake
Kathryn V Blake
DWDebbie Wilson
Debbie Wilson
AWAlmut G Winterstein
Almut G Winterstein
HPHaesuk Park
Haesuk Park
Background: Little is known about economic and productivity loss by severity of asthma. We investigate health-care utilization, direct medical costs, and indirect costs due to productivity loss from asthma by severity. Methods: We conducted a cross-sectional analysis of the Medical Expenditure Panel Survey database (2010– 2017) of patients with asthma aged ≥ 12 years and categorized them into mild, moderate, and severe asthma groups based on symptom control medications. Study outcomes included health-care utilization, direct medical costs, and indirect costs of asthma-related absenteeism. We used zero-inflated Poisson regression models to estimate incremental health-care utilization and generalized linear models to estimate incremental annual direct medical costs compared to patients without asthma. Results: An estimated 139 million persons had an asthma diagnosis. Of patients with asthma, 77.1%, 22.2%, and 0.7% had mild, moderate, and severe asthma, respectively. Compared to patients without asthma, patients with asthma had incremental mean differences of 4.16 outpatient visits, 0.18 emergency department visits, and 0.07 hospitalizations per year. Annual direct medical costs were significantly associated with asthma severity ($3305 in mild, $7250 in moderate, and $9175 in severe asthma) (P < 0.05). Patients with mild, moderate, and severe asthma reported 0.76, 2.31, and 7.19 missed work or school days, resulting in $106, $321, and $1000 indirect costs per person per year, respectively. Conclusion: Asthma-related direct and indirect costs are significantly associated with asthma severity, with severe asthma medical costs being about three times higher than mild. Controlling asthma symptoms is important to reduce the economic and social burden of asthma.

1 November 2008 in Chest
Verified
Journal Article
Closed access
PDF file
KBKathryn Blake
Kathryn Blake
RMRajanikanth Madabushi
Rajanikanth Madabushi
HDHartmut Derendorf
Hartmut Derendorf
JLJohn Lima
John Lima

1 May 2015 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
KBKathryn Blake
Kathryn Blake
JHJanet T. Holbrook
Janet T. Holbrook
HAHolly Antal
Holly Antal
DSDavid Shade
David Shade
HBH. Timothy Bunnell
H. Timothy Bunnell
TWTim Wysocki
Tim Wysocki

25 September 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
STSony Tuteja
Sony Tuteja
RSRamzi Salloum
Ramzi Salloum
AEAmanda Leigh Elchynski
Amanda Leigh Elchynski
DSD. Max Smith
D. Max Smith
ERElizabeth Rowe
Elizabeth Rowe
FGfor the IGNITE Pharmacogenetics Working Group
for the IGNITE Pharmacogenetics Working Group
There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented or were in the process of implementing PGx testing for antidepressants. Survey 1 collected data on the process and logistics of testing. Survey 2 asked sites to rank the importance of Consolidated Framework for Implementation Research (CFIR) constructs using best‐worst scaling choice experiments. Of the 17 sites, 13 had implemented testing and four were in the planning stage. Thirteen offered testing in the outpatient setting, and nine in both outpatient/inpatient settings. PGx tests were mainly ordered by psychiatry (92%) and primary care (69%) providers. CYP2C19 and CYP2D6 were the most commonly tested genes. The justification for antidepressants selected for PGx guidance was based on Clinical Pharmacogenetics Implementation Consortium guidelines (94%) and US Food and Drug Administration (FDA; 75.6%) guidance. Both institutional (53%) and commercial laboratories (53%) were used for testing. Sites varied on the methods for returning results to providers and patients. Sites were consistent in ranking CFIR constructs and identified patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and the identification of champions as most important for implementation. Sites deployed similar implementation strategies and measured similar outcomes. The process of implementing PGx testing to guide antidepressant therapy varied across sites, but key drivers for successful implementation were similar and may help guide other institutions interested in providing PGx‐guided pharmacotherapy for antidepressant management.

1 July 2021 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
HSHyun Jin Song
Hyun Jin Song
KBKathryn V Blake
Kathryn V Blake
DWDebbie Wilson
Debbie Wilson
AWAlmut G Winterstein
Almut G Winterstein
HPHaesuk Park
Haesuk Park
Background: Little information is known about the health-related quality of life (HRQOL) and the patient’s preference values by the severity of asthma. We evaluated the HRQOL and health utility impairment associated with asthma severity using the SF-12 and SF-6D. Methods: We conducted a cross-sectional analysis of 2010– 2016 Medical Expenditure Panel Survey database of asthma patients aged ≥ 18 years and categorized them into mild, moderate, and severe asthma. Study outcomes included the SF-12 physical component summary (PCS) and mental component summary (MCS) for measuring HRQOL and SF-6D for health utility. Survey regression models were used to estimate HRQOL and utilities for mild, moderate, and severe asthma. Results: Of 10,222 patients with asthma, 75.4%, 23.9%, and 0.8% had mild, moderate and severe asthma. We observed that the greater the severity, the lower the SF-6D scores: 0.731 in mild, 0.723 in moderate, and 0.659 in severe asthma (P < 0.001). Patients with severe asthma had a significantly lower PCS compared to those with mild asthma (− 5.3; P < 0.001) but there was no significant difference in MCS (− 1.9; P = 0.309) controlling for socioeconomic and clinical variables. Asthma severity, women, older age, and having a lower level education and public insurance were significantly associated with lower PCS (P < 0.01). Conclusion: Asthma patients had worse physical HRQOL than mental health, especially patients with severe asthma. These data suggest that the management of physical health of female, older aged, and low education patients with asthma should be focused on improving HRQOL.